

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
23 December 2004 (23.12.2004)

PCT

(10) International Publication Number  
**WO 2004/111046 A2**

(51) International Patent Classification<sup>7</sup>: **C07D 417/12**

(21) International Application Number:  
PCT/EP2004/006425

(22) International Filing Date: 14 June 2004 (14.06.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
0313914.4 16 June 2003 (16.06.2003) GB

(74) Agent: ROWDEN, Janette, Yvonne; GlaxoSmithKline,  
Corporate Intellectual Property CN925.1, 980 Great West  
Road, Brentford Middlesex TW8 9GS (GB).

(81) Designated States (*unless otherwise indicated, for every  
kind of national protection available*): AE, AG, AL, AM,  
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,  
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,  
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,  
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,  
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,  
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,  
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,  
ZW.

(71) Applicant (*for all designated States except US*):  
**SMITHKLINE BEECHAM CORPORATION**  
[US/US]; One Franklin Plaza, P.O. Box 7929, Philadel-  
phia, PA 19101 (US).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **DODIC, Ner-  
ina** [FR/FR]; Laboratoire GlaxoSmithKline, Centre de  
Recherches, ZA de Courtaboeuf, 25, avenue du Quebec,  
F-91951 Les Ulis (FR). **DONCHE, Frederic** [FR/FR];  
Laboratoire GlaxoSmithKline, Centre de Recherches,  
ZA de Courtaboeuf, 25, avenue du Quebec, F-91951 Les  
Ulis (FR). **GELLIBERT, Francoise, Jeanne** [FR/FR];  
Laboratoire GlaxoSmithKline, Centre de Recherches, ZA  
de Courtaboeuf, 25, avenue du Quebec, F-91951 Les Ulis  
(FR).

(84) Designated States (*unless otherwise indicated, for every  
kind of regional protection available*): ARIPO (BW, GH,  
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,  
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,  
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,  
SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,  
GW, ML, MR, NE, SN, TD, TG).

**Published:**

— *without international search report and to be republished  
upon receipt of that report*

*For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.*

(54) Title: COMPOUNDS

(57) Abstract: The invention relates to novel aminothiazole derivatives which are inhibitors of the transforming growth factor, ("TGF")-B signaling pathway, in particular, the phosphorylation of smad2 or smad3 by the TGF-B type I or activin-like kinase ("ALK")-5 receptor, methods for their preparation and their use in medicine, specifically in the treatment and prevention of a disease state mediated by this pathway.

WO 2004/111046 A2